• Positive preliminary unblinded efficacy results reported from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial in relapsed or refractory AML.
• Early efficacy trends observed across both Annamycin treatment arms in the randomized, double-blind, placebo-controlled study of Annamycin plus cytarabine.
• Management highlighted commercial opportunity, citing recent market research on the potential addressable market for Annamycin if approved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.